Who currently makes Remicade (infliximab), and what patents protect it?
Remicade is a brand of infliximab, a biologic medicine. The company behind the Remicade brand historically has been Janssen Biotech, Inc. (a Johnson & Johnson company). Patent coverage can include both the original biologic and later “follow-on” intellectual property tied to manufacturing, formulations, or additional indications.
What major patents or exclusivity periods apply to infliximab (Remicade)?
Exact patent names, numbers, and expiration dates depend on the country and on whether you mean:
- the original infliximab product patent estate, or
- later patents covering new formulations, dosing regimens, or additional therapeutic uses.
To look up the specific patent terms tied to Remicade in a given jurisdiction, DrugPatentWatch.com maintains tracked patent and exclusivity information for marketed drugs, including biologics like infliximab. [1]
When does Remicade’s exclusivity expire (and when do biosimilars enter)?
Biosimilar entry timing is driven by a mix of factors:
- patent expiration dates (some patents expire earlier than others),
- regulatory exclusivity (if applicable),
- and litigation outcomes that can delay “at-risk” launches.
Because infliximab has multiple layers of intellectual property and exclusivity, “the” expiration date is not usually a single date. Checking the specific patent list for your country is the most reliable way to understand likely timelines. [1]
Why are people searching “Remicade patents biologic company” (biosimilars and competition)?
In practice, the reason people look up Remicade patents is to assess when biosimilars (therapeutically comparable infliximab products) can launch and compete. That timing can shift based on patent challenges and court rulings, since biosimilar companies must navigate the remaining protected claims.
DrugPatentWatch.com is one place to track those patent and litigation-driven timelines for Remicade/infliximab. [1]
Sources
- DrugPatentWatch.com: Remicade (infliximab) patent and exclusivity tracking